Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation ; volume:10 ; number:1 ; day:4 ; month:11 ; year:2022 ; pages:1-15 ; date:12.2022
Acta Neuropathologica Communications ; 10, Heft 1 (4.11.2022), 1-15, 12.2022
- Urheber
-
Lakis, Nelli S.
Brodsky, Alexander S.
Karashchuk, Galina
Audesse, Amanda J.
Yang, Dongfang
Sturtevant, Ashlee
Lombardo, Kara
Wong, Ian Y.
Webb, Ashley E.
Anthony, Douglas C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-022-01459-9
- URN
-
urn:nbn:de:101:1-2023011921252572406221
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lakis, Nelli S.
- Brodsky, Alexander S.
- Karashchuk, Galina
- Audesse, Amanda J.
- Yang, Dongfang
- Sturtevant, Ashlee
- Lombardo, Kara
- Wong, Ian Y.
- Webb, Ashley E.
- Anthony, Douglas C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial